Australia markets close in 4 hours 59 minutes

argenx SE (ARGX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
373.47+9.12 (+2.50%)
At close: 04:00PM EDT
373.75 +0.28 (+0.07%)
After hours: 06:56PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close364.35
Open365.92
Bid373.81 x 1200
Ask550.06 x 800
Day's range364.43 - 376.55
52-week range249.50 - 376.55
Volume227,983
Avg. volume304,883
Market cap20.256B
Beta (5Y monthly)1.03
PE ratio (TTM)N/A
EPS (TTM)-11.53
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est390.74
  • GlobeNewswire

    argenx Receives Positive CHMP Opinion for Efgartigimod for the Treatment of Adult Patients with Generalized Myasthenia Gravis in Europe

    Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measuresEuropean Commission decision on marketing authorization application (MAA) expected in approximately 60 days If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG) Breda, the Netherlands—June 24, 2022—argenx (Eur

  • GlobeNewswire

    argenx to Present at Upcoming Investor Conferences

    June 1, 2022Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of management will participate in several upcoming investor conferences in June: Jefferies 2022 Global Healthcare Conference. Fireside chat on Wednesday, June 8, 2022 at 1:00 p.m. ET in New York, NY.Goldman Sachs 43rd Annual Global Healthcare Conference. Fireside chat on Wednesday, Jun

  • GlobeNewswire

    argenx Announces the UK MHRA has Granted Early Access to Efgartigimod for Generalized Myasthenia Gravis

    Positive scientific opinion under Early Access to Medicines Scheme (EAMS) will make efgartigimod available to eligible generalized myasthenia gravis (gMG) patients in the UK prior to marketing authorization Efgartigimod was granted a Promising Innovative Medicine (PIM) designation by UK’s Medicines and Healthcare products Regulatory Agency (MHRA) in November 2021 Breda, the Netherlands—May 31, 2022—argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives